Top adjuvant chemotherapy Articles in Pulmonology

Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeons
Medical Oncology, 10/01/2009

Shukuya T et al. – This study revealed that there were considerable differences in whether patients consented to adjuvant ... chemotherapy depending on the medical oncologists that they were referred to, and suggested possible differences in the judgment of the patients’ suitability for adjuvant chemotherapy among surgeons. [more...]

Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas
Clinical Neurology and Neurosurgery, 10/16/2009

Rhee DJ et al. – Adjuvant TMZ chemotherapy provided a clinically relevant benefit of survival, as compared with NUBC. Thus, the authors suggest that adjuvant TMZ chemotherapy may be effective [more...]

Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven
The Oncologist, 10/28/2009

Blay J–Y et al. – The authors conclude that adjuvant chemotherapy has not been proven to improve the outcome of an unselected population of patients. Several hypotheses are proposed to account for this ... observation. [more...]

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/2009

Trudeau ME et al. – Anthracyclines are a component of breast cancer chemotherapy regimens in both adjuvant and metastatic settings. Anthracycline rechallenge for metastatic disease, for those previously exposed to adjuvant anthracyclines, may not be ... PLD plus cyclophosphamide is effective and well tolerated in patients with metastatic breast cancer who have received prior adjuvant anthracycline-containing chemotherapy. The majority of patients experienced a clinical benefit without any significant impact on cardiac function Methods Delivered every 3 weeks, in 70 patients who developed metastatic disease more than 12 months after completion of an adjuvant anthracycline-containing regimen 7 patients discontinued treatment early and excluded from efficacy analysis Results [more...]

Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands
Annals of Oncology, 11/04/2009

van Steenbergen LN et al. – The purpose was to assess factors associated with the administration of chemotherapy and their relation to survival at a population–based level. Adherence to guidelines for adjuvant ... chemotherapy was still suboptimal in 2007, especially for elderly patients, and differed widely between hospitals. [more...]

Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy
Breast Cancer Research and Treatment, 10/12/2009

Kimet HS et al. – Overexpression of p53 is significantly associated with tamoxifen resistance in premenopausal women with breast cancer. Methods adjuvant therapy, breast cancer-specific survival (BCSS), and RFS in patients with primary breast cancer Results Overexpression of p53 was noted in 1,091 patients Significant correlation existed ... 50, and >50 years) and adjuvant therapy (hormone therapy only, chemotherapy only, and hormone therapy following chemotherapy), greatest reduction of survival based on p53 overexpression noted in patients 35–50 years of age who received hormone therapy following chemotherapy Multivariate ... independent prognostic factor in patients treated with hormone therapy and chemotherapy p53-overexpressing patients with breast cancer between 35 and 50 years of age who received tamoxifen following chemotherapy had greatest adverse effect on outcome [more...]

Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma
Head & Neck, 11/09/2009

Mendenhal WM et al. – Altered fractionation and/or concomitant chemotherapy result in improved outcomes compared with conventionally fractionated definitive RT alone for stage III–stage IV HNSCC ... RT fractionation and chemotherapy remains unclear. [more...]

Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy
The Oncologist, 10/28/2009

Schuetze SM et al. – In multiple analyses, patients with high–risk soft tissue sarcoma treated with chemotherapy have a >10% absolute lower risk for disease recurrence and longer disease–specific survival than patients treated without chemotherapy. In the ... absence of conclusive results from an adequately powered, randomized, controlled clinical trial, the available data support the use of chemotherapy in the management of high–risk, localized, soft tissue sarcoma. [more...]

The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study
European Journal of Cancer, 10/14/2009

Rosendahl M et al. – Amenorrhoea is a common side-effect to chemotherapy of premenopausal women ... examine the association between chemotherapy-induced leucopaenia and the development of amenorrhoea in premenopausal women with breast cancer. Age is the most important risk factor of amenorrhoea after FEC chemotherapy. However, for younger patients, lower leukocyte nadir in response to STANDARD FEC [more...]

Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/2009

with HER2-negative tumors receiving first-line docetaxel-based chemotherapy for advanced breast cancer. After multivariate analysis, only three independent variables for PFS (HR-positive tumor, no prior adjuvant/neoadjuvant chemotherapy, and isolated bone metastases) and two for OS (HR-positive ... b>Methods Medical charts of 162 patients with prospectively proven HER2-negative ABC and having received docetaxel as first-line chemotherapy for metastatic disease retrospectively reviewed Special emphasis on docetaxel efficacy Potential prognostic factors sought ... analysis for both PFS and OS After multivariate analysis, only 3 independent variables for PFS (HR-positive tumor, no prior adjuvant/neoadjuvant chemotherapy, and isolated bone metastases) and 2 for OS (HR-positive tumor and isolated bone metastases) remained predictive of a favorable [more...]